Moreover, MET phosphorylates PARP1 at pTyr907, which increases PARP1 enzyme activity and reduces the binding capacity of PARP inhibitors, resulting in drug resistance; while inhibition of MET enhances the antitumour effect of PARP inhibitors,18 but whether targeting MET also can improve the antitumour effect of PARP inhibitors in PC is currently unknown. The gene discussed is PARP1; the disease is pachyonychia congenita.